CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

FDA looks into reassessing criteria around rare disease trials, endpoint selection

RegulatoryNeutral
AI Analysis

Summary

The FDA announced it is seeking external input on reassessing criteria for rare disease trials, specifically regarding efficacy and safety data sufficiency and endpoint selection methodologies.

Importance:4/10
Sentiment:
0.00
rare diseaseFDA guidanceendpoint selectionefficacysafety data

Read the original article

Published by Endpoints News on September 14, 2026 6:05 PM

Read Original